§2159.2. Substance use disorder facilities treating pregnant women
A.(1) Each substance use disorder facility licensed pursuant to this Part as a
behavioral health services provider that provides treatment for opioid use disorder to
pregnant women shall provide onsite access to at least one form of FDA-approved opioid
agonist treatment.
(2) For purposes of this Section, "onsite access" shall mean delivery of the treatment
to the patient at the location of the substance use disorder facility. "Onsite access" shall not
mean that the substance use disorder facility is required to maintain stock of the
medication-assisted treatment at the facility.
(3) A substance use disorder facility shall not be found to be in violation of this
Section if prior authorization from a patient's health insurer, including the Medicaid program,
is required and the preapproval request is denied by the patient's health insurer.
B. Each substance use disorder facility licensed pursuant to this Part as a behavioral
health services provider which provides treatment for opioid use disorder to pregnant women
shall submit to the department on its initial licensing application or its annual licensing
renewal application an attestation as to whether it is complying with the requirements of
Subsection A of this Section. The requirement for submission of the attestation shall
commence on January 1, 2023. If the licensed facility is not fully complying with the
requirements of Subsection A of this Section, then the attestation that the facility submits
shall include a report addressing its progress toward satisfying those requirements.
Acts 2022, No. 309, §1, eff. Jan. 1, 2023.